Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1993 1
1999 7
2002 5
2003 1
2004 4
2005 2
2006 1
2007 1
2008 2
2009 2
2011 1
2012 3
2013 3
2014 2
2015 1
2016 4
2017 3
2018 8
2019 8
2020 10
2021 5
2022 6
2023 3
2024 3

Text availability

Article attribute

Article type

Publication date

Search Results

74 results

Results by year

Filters applied: . Clear all
Page 1
PLP1 Disorders.
Wolf NI, van Spaendonk RML, Hobson GM, Kamholz J. Wolf NI, et al. Among authors: kamholz j. 1999 Jun 15 [updated 2019 Dec 19]. In: Adam MP, Feldman J, Mirzaa GM, Pagon RA, Wallace SE, Bean LJH, Gripp KW, Amemiya A, editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993–2024. 1999 Jun 15 [updated 2019 Dec 19]. In: Adam MP, Feldman J, Mirzaa GM, Pagon RA, Wallace SE, Bean LJH, Gripp KW, Amemiya A, editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993–2024. PMID: 20301361 Free Books & Documents. Review.
Post-COVID-19 Fatigue: Potential Contributing Factors.
Rudroff T, Fietsam AC, Deters JR, Bryant AD, Kamholz J. Rudroff T, et al. Among authors: kamholz j. Brain Sci. 2020 Dec 19;10(12):1012. doi: 10.3390/brainsci10121012. Brain Sci. 2020. PMID: 33352638 Free PMC article.
Pepinemab antibody blockade of SEMA4D in early Huntington's disease: a randomized, placebo-controlled, phase 2 trial.
Feigin A, Evans EE, Fisher TL, Leonard JE, Smith ES, Reader A, Mishra V, Manber R, Walters KA, Kowarski L, Oakes D, Siemers E, Kieburtz KD, Zauderer M; Huntington Study Group SIGNAL investigators. Feigin A, et al. Nat Med. 2022 Oct;28(10):2183-2193. doi: 10.1038/s41591-022-01919-8. Epub 2022 Aug 8. Nat Med. 2022. PMID: 35941373 Free PMC article. Clinical Trial.
Phenotypic clustering in MPZ mutations.
Shy ME, Jáni A, Krajewski K, Grandis M, Lewis RA, Li J, Shy RR, Balsamo J, Lilien J, Garbern JY, Kamholz J. Shy ME, et al. Among authors: kamholz j. Brain. 2004 Feb;127(Pt 2):371-84. doi: 10.1093/brain/awh048. Epub 2004 Jan 7. Brain. 2004. PMID: 14711881 Review.
Safety and efficacy of laquinimod for Huntington's disease (LEGATO-HD): a multicentre, randomised, double-blind, placebo-controlled, phase 2 study.
Reilmann R, Anderson KE, Feigin A, Tabrizi SJ, Leavitt BR, Stout JC, Piccini P, Schubert R, Loupe P, Wickenberg A, Borowsky B, Rynkowski G, Volkinshtein R, Li T, Savola JM, Hayden M, Gordon MF; LEGATO-HD Study Group. Reilmann R, et al. Lancet Neurol. 2024 Mar;23(3):243-255. doi: 10.1016/S1474-4422(23)00454-4. Epub 2024 Jan 24. Lancet Neurol. 2024. PMID: 38280392 Clinical Trial.
Statin use and delayed onset of Huntington's disease.
Schultz JL, Nopoulos PC, Killoran A, Kamholz JA. Schultz JL, et al. Among authors: kamholz ja. Mov Disord. 2019 Feb;34(2):281-285. doi: 10.1002/mds.27591. Epub 2018 Dec 21. Mov Disord. 2019. PMID: 30576007
74 results